Cancer Invest. 2010 Feb;28(2):172-80.

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G.

Source

Medical Oncology, Regina Elena Cancer Institute, via Elio Chianesi 53 00144 Rome, Italy. giulio.metro@yahoo.com

Abstract

Ribonucleotide reductase 1 (RRM1) is a determinant of gemcitabine efficacy in non-small-cell lung cancer and pancreatic cancer. We investigated the protein levels of RRM1 and two other DNA repair enzymes, ERCC1 and BRCA1, in 55 metastatic breast cancer (MBC) patients undergoing gemcitabine-based chemotherapy. With automated in situ protein quantification (AQUA v1.6), the average scores for RRM1, ERCC1, and BRCA1 ranged from 245.6-2774.1, 74.0-410.3, and 54.4-1833.1, respectively. They were significantly associated with each other (Spearman's rho > or = .36; p < or = .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC.

PMID:: 19968494; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Supplemental Content

Save items

Related citations in PubMed

The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. [J Korean Med Sci. 2011]
The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.
Kim D, Jung W, Koo JS. J Korean Med Sci. 2011 Mar; 26(3):352-9. Epub 2011 Feb 25.
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. [PLoS One. 2008]
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, et al. PLoS One. 2008; 3(11):e3695. Epub 2008 Nov 11.
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. [Clin Cancer Res. 2004]
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P, et al. Clin Cancer Res. 2004 Feb 15; 10(4):1318-25.
Review Influence of genetic markers on survival in non-small cell lung cancer. [Drugs Today (Barc). 2003]
Review Influence of genetic markers on survival in non-small cell lung cancer.
Rosell R, Taron M, Camps C, López-Vivanco G. Drugs Today (Barc). 2003 Oct; 39(10):775-86.
Review Pharmacogenomics and gemcitabine. [Ann Oncol. 2006]
Review Pharmacogenomics and gemcitabine.
Rosell R, Cobo M, Isla D, Camps C, Massuti B. Ann Oncol. 2006 May; 17 Suppl 5:v13-16.

See reviews... See all...

Cited by 3 PubMed Central articles

The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. [J Korean Med Sci. 2011]
The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.
Kim D, Jung W, Koo JS. J Korean Med Sci. 2011 Mar; 26(3):352-9. Epub 2011 Feb 25.
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. [Am J Pathol. 2011]
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis.
Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, et al. Am J Pathol. 2011 Jan; 178(1):69-78. Epub 2010 Dec 23.
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. [Breast Cancer Res. 2010]
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.
Parisi F, González AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y. Breast Cancer Res. 2010 Sep 1; 12(5):R66. Epub 2010 Sep 1.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer...
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Cancer Invest. 2010 Feb ;28(2):172-80.

PubMed
Stopped-flow fluorescence kinetic studies of Glu-plasminogen. Conformational cha...
Stopped-flow fluorescence kinetic studies of Glu-plasminogen. Conformational changes triggered by AH-site ligand binding.
FEBS Lett. 1991 Jan 28 ;278(2):204-6.

PubMed
Molecular imaging of breast cancer.
Molecular imaging of breast cancer.
Breast. 2009 Oct ;18 Suppl 3:S66-73.

PubMed
Genetic analysis of breast cancer in the cancer and steroid hormone study.
Genetic analysis of breast cancer in the cancer and steroid hormone study.
Am J Hum Genet. 1991 Feb ;48(2):232-42.

PubMed
Ku proteins interact with activator protein-2 transcription factors and contribu...
Ku proteins interact with activator protein-2 transcription factors and contribute to ERBB2 overexpression in breast cancer cell lines.
Breast Cancer Res. 2009 ;11(6):R83. Epub 2009 Nov 11 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Libraries

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information